July 25, 2014 5:22 AM ET


Company Overview of Five Prime Therapeutics, Inc.

Company Overview

Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of protein therapeutics that block cancer and inflammatory disease processes. The company’s product candidates include FP-1039/GSK3052230, a protein therapeutic, which is in Phase 1b clinical trials for trapping and neutralizing cancer-promoting fibroblast growth factors (FGFs) involved in cancer cell proliferation and new blood vessel formation; FPA008, a Phase 1 clinical trial stage antibody that inhibits colony stimulating factor-1 receptor; and FPA144 is an antibody for inhibiting FGF receptor 2b, as well as to treat patients with gastric cancer and potentially other solid tumo...

Two Corporate Drive

South San Francisco, CA 94080

United States

Founded in 2001

105 Employees





Key Executives for Five Prime Therapeutics, Inc.

Age: 65
Total Annual Compensation: $525.0K
Chief Business Officer
Age: 45
Total Annual Compensation: $362.8K
Chief Medical Officer and Senior Vice President
Age: 56
Total Annual Compensation: $350.0K
Senior Vice President
Age: 43
Total Annual Compensation: $311.9K
Compensation as of Fiscal Year 2013.

Five Prime Therapeutics, Inc. Key Developments

Five Prime Therapeutics, Inc. Presents at Jefferies 2014 Global Healthcare Conference, Jun-04-2014 01:30 PM

Five Prime Therapeutics, Inc. Presents at Jefferies 2014 Global Healthcare Conference, Jun-04-2014 01:30 PM. Venue: Grand Hyatt, New York, New York, United States. Speakers: Julie Hambleton, Chief Medical Officer and Senior Vice President, Lewis T. Williams, Founder, Chief Executive Officer, President and Director.

Five Prime Therapeutics, Inc. Reports Financial Results for the First Quarter Ended March 31, 2014; Provides Cash Flow Guidance for the Full Year of 2014

Five Prime Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2014. For the quarter, the company reported collaboration revenue increased 17% to $3.5 million from $3.0 million in the first quarter of 2013. This increase was primarily attributed to revenue earned under the fibrosis and CNS collaboration with UCB initiated in March 2013. Loss from operations was $8,660,000 compared to $7,347,000 last year. Net loss was $8.6 million, or $0.46 per basic and diluted share, compared to a net loss of $7.0 million, or $5.73 per basic and diluted share, for the first quarter of 2013. This increase in net loss was primarily due to the advancement of FPA144 towards a fourth quarter 2014 IND submission and public company-related expenses. The company continues to expect full-year 2014 net cash used in operating activities to be less than $30 million.

Five Prime Therapeutics, Inc. to Report Q1, 2014 Results on May 08, 2014

Five Prime Therapeutics, Inc. announced that they will report Q1, 2014 results After-Market on May 08, 2014

Similar Private Companies By Industry

Company Name Region
miRagen Therapeutics, Inc. United States
Champion Investments, Inc. United States
AdvanDx, Inc. United States
PhaseRx, Inc. United States
Keystone Analytical Inc. United States

Recent Private Companies Transactions

Private Placement
March 19, 2014

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Five Prime Therapeutics, Inc., please visit www.fiveprime.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.